Joseph Oliveto
Chief Executive Officer at MILESTONE PHARMACEUTICALS INC.
Net worth: 450 578 $ as of 2024-04-29
Profile
Joseph G.
Oliveto is currently the President, Chief Executive Officer & Director at Milestone Pharmaceuticals, Inc. and the President & Chief Executive Officer at Milestone Pharmaceuticals USA, Inc. He previously held positions as the President, Chief Executive Officer & Director at Chelsea Therapeutics International Ltd., the Chief Executive Officer & Director at Galleon Pharmaceuticals, Inc., the Director-Global Alliance at Hoffmann-La Roche, Inc., and the Executive-in-Residence at Pappas Capital LLC.
Mr. Oliveto obtained his undergraduate degree and MBA from Rutgers State University of New Jersey.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-04-14 | 285,176 ( 0.54% ) | 450 578 $ | 2024-04-29 |
Joseph Oliveto active positions
Companies | Position | Start |
---|---|---|
MILESTONE PHARMACEUTICALS INC. | Chief Executive Officer | 2017-03-06 |
Milestone Pharmaceuticals USA, Inc.
Milestone Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Part of Milestone Pharmaceuticals, Inc., Milestone Pharmaceuticals USA, Inc. develops cardiovascular drugs. The company is based in Charlotte, NC. Joseph G. Oliveto has been the CEO of the company since 2017. | Chief Executive Officer | 2017-03-06 |
Former positions of Joseph Oliveto
Companies | Position | End |
---|---|---|
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | Chief Executive Officer | 2016-05-31 |
CHELSEA THERAPEUTICS INTERNATIONAL LTD. | Chief Executive Officer | 2014-06-22 |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Corporate Officer/Principal | 2008-06-29 |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | 2007-12-31 |
Training of Joseph Oliveto
Rutgers State University of New Jersey | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
MILESTONE PHARMACEUTICALS INC. | Health Technology |
Private companies | 5 |
---|---|
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Finance |
Chelsea Therapeutics International Ltd.
Chelsea Therapeutics International Ltd. BiotechnologyHealth Technology Chelsea Therapeutics International Ltd. acquires, develops and commercializes innovative products for the treatment of a variety of human diseases. The company was founded by Simon C. Pedder on June 17, 2005 and is headquartered in Charlotte, NC. | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | Health Technology |
Milestone Pharmaceuticals USA, Inc.
Milestone Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Part of Milestone Pharmaceuticals, Inc., Milestone Pharmaceuticals USA, Inc. develops cardiovascular drugs. The company is based in Charlotte, NC. Joseph G. Oliveto has been the CEO of the company since 2017. | Health Technology |
- Stock Market
- Insiders
- Joseph Oliveto